Expertise in
12
conditions

Dr. Nitin Jain

Radiology
Henry Ford St. John Hospital
22101 Moross Rd, 
Detroit, MI 
Referral may be required
Expertise in
12
conditions
Henry Ford St. John Hospital
22101 Moross Rd, 
Detroit, MI 

Overview

Nitin Jain is a Radiologist practicing medicine in Detroit, Michigan.

Dr. Jain is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Small Lymphocytic Lymphoma (SLL), Ascites, Bone Marrow Aspiration, and Endoscopy.

He is actively involved in clinical research, co-authoring 557 peer reviewed articles and participating in 14 clinical trials.

Specialties

Radiology

Licenses

Diagnostic Radiology in MI

Hospital Affiliations

Henry Ford Health Warren Hospital
Henry Ford Health St John Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Henry Ford St. John Hospital
22101 Moross Rd, Detroit, MI 48236
Other Locations
Henry Ford Warren Hospital
11800 E 12 Mile Rd, Warren, MI 48093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears: A Multicenter Randomized Controlled Pragmatic Trial
Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears: A Multicenter Randomized Controlled Pragmatic Trial
Enrollment Status: Completed
Publish Date: March 30, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2026
Intervention Type: Drug, Biological
Study Drugs: Cyclophosphamide, Fludarabine, Ibrutinib, Obinutuzumab
Study Phase: Phase 2
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 19, 2026
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Venetoclax
Study Phase: Phase 2
Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia and Richter Transformation
Enrollment Status: Active_not_recruiting
Publish Date: February 17, 2026
Intervention Type: Biological, Other, Drug
Study Drugs: Atezolizumab, Obinutuzumab, Venetoclax
Study Phase: Phase 2
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: December 12, 2025
Intervention Type: Biological
Study Drug: ADCT-602 Monoclonal Antibody
Study Phase: Phase 1/Phase 2
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Terminated
Publish Date: June 08, 2025
Intervention Type: Drug, Biological, Other
Study Phase: Phase 2
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: MS-553
Study Phase: Phase 1/Phase 2
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Ipilimumab Combined With Ibrutinib and Nivolumab for Patients With Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)
Enrollment Status: Withdrawn
Publish Date: February 28, 2025
Intervention Type: Drug, Biological
Study Drugs: Ibrutinib, Ipilimumab, Nivolumab
Study Phase: Phase 1
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Completed
Publish Date: March 20, 2024
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Nivolumab
Study Phase: Phase 2
View 9 Less Clinical Trials

557 Total Publications

Trends and risk factors for spinal cord injury-induced heterotopic ossification: A retrospective population-based cross-sectional study using the 2016-2021 National Inpatient Sample (NIS).
Trends and risk factors for spinal cord injury-induced heterotopic ossification: A retrospective population-based cross-sectional study using the 2016-2021 National Inpatient Sample (NIS).
Journal: The journal of spinal cord medicine
Published: March 24, 2026
Similar Doctors
Expertise in
44
conditions
Dr. Ella A. Kazerooni
Radiology
Expertise in
44
conditions
Dr. Ella A. Kazerooni
Radiology

U Of M Radiology

1500 E Medical Center Dr, 
Ann Arbor, MI 
 (40.0 miles away)
734-936-4500
Languages Spoken:
English
See accepted insurances

Ella Kazerooni is a Radiologist practicing medicine in Ann Arbor, Michigan. Dr. Kazerooni is highly rated in 44 conditions, according to our data. Her clinical expertise encompasses Lung Nodules, Emphysema, Interstitial Lung Disease, Pulmonary Fibrosis, and Transcatheter Aortic Valve Replacement (TAVR).

Expertise in
22
conditions
Dr. Peter Winston
Radiology
Expertise in
22
conditions
Dr. Peter Winston
Radiology

Michigan Institute Of Urology PC

20952 E 12 Mile Rd Ste 200, 
Saint Clair Shores, MI 
 (5.6 miles away)
586-771-4820
Languages Spoken:
English
See accepted insurances

Peter Winston is a Radiologist practicing medicine in Saint Clair Shores, Michigan. Dr. Winston is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Carbuncle, Folliculitis, Boils, and WT1-Related Wilms Tumor Syndromes.

Expertise in
51
conditions
Dr. Anthony Alcantara
Radiology
Expertise in
51
conditions
Dr. Anthony Alcantara
Radiology

St. John Hospital And Medical Center

22101 Moross Rd, 
Detroit, MI 
 (7.5 miles away)
313-343-3545
Languages Spoken:
English
See accepted insurances

Anthony Alcantara is a Radiologist practicing medicine in Detroit, Michigan. Dr. Alcantara is highly rated in 51 conditions, according to our data. His clinical expertise encompasses Pleurisy, Pleural Effusion, Lung Nodules, and Gallbladder Disease.

Frequently Asked Questions about Dr. Nitin Jain

How do I make an appointment with Dr. Nitin Jain?

You can book an appointment with Dr. Nitin Jain by calling their office at 313-343-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nitin Jain a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nitin Jain is classified as an Elite expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nitin Jain specialize in?

While Dr. Nitin Jain is a Radiology, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Small Lymphocytic Lymphoma (SLL), and Ascites. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiology.

Does Dr. Nitin Jain participate in research or clinical trials?

Yes. Dr. Nitin Jain has published 557 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Nitin Jain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nitin Jain accept my insurance?

Dr. Nitin Jain accepts most major insurance plans, including Blue Cross Blue Shield and Health Alliance Plan. We recommend calling the office directly at 313-343-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile